Insmed Drug Misses Primary Goal, Program Axed

Insmed Incorporated (NASDAQ:INSM) on Tuesday shared the Phase 2b CEDAR study results for brensocatib. The study did not meet its primary or secondary efficacy endpoints, leading Insmed to discontinue its hidradenitis suppurativa program. Insmed Discontinues Failed...